Mizuho notes that Verastem's abstract regarding its Phase II study in KRAS mutated lung cancer noted two deaths that it said were "possibly related to" defactinib in the trial. However, the firm feels the term "possibly related" is likely used more-or-less automatically in circumstances like these and noted that adverse events have not been significant issues in the drug's other trials, including the COMMAND mesothelioma study. Mizuho, which expects to get more details at the conference, reiterates its Buy rating and $21 price target on Verastem shares.